ANN ARBOR, Mich., May 20, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced the appointments of Sharon Watling, Pharm.D., as vice president, clinical and regulatory, and Ronnda L. Bartel, Ph.D., formerly vice president of technical operations, as chief scientific officer.
